Introduction
Through the impact of molecular biology and particularly of gene cloning, the number of dopamine (DA) receptors identified continues to increase. T h e era of the classical DJD, nomenclature [ 1,2] has been followed by identification and parcellation of two families of 'DI-like' (DIA and DIB, or DI and D5) and IDz-like' (DZLIS, D3 and D4) receptors, with subsequent recognition of multiple splice and polymorphic variants thereof [3-71; very recently, putative Dlc [8] and DID [9] entities have been identified, together with a putative primordial 'DI-like' entity [lo] characterized by paradoxically poor affinity for those benzazepine drugs that are otherwise recognized ubiquitously by their DIA-D counterparts. Such developments, while exciting and heuristic, perpetuate and exacerbate the problem of delineating the distinct physiological roles of these mulitple DA receptor subtypes in the absence of a complete armamentarium of subtype-specific agonist and antagonist drugs as probes for functional studies. For example, drugs that bind selectively to members of the 'Dl-like' or of the IDz-like' family are little able to dis-*To whom correspondence should be addressed. criminate between individual members within each family [3] [4] [5] [6] [7] 11, 12] .
T h e majority of studies on DA receptor subtype function have concerned the roles of D, and D2 receptors, which are now recognized to encompass generically the 'D,-like' and 'Dz-like' families. Although receptor function can be examined at multiple physiological levels, from local cellular transduction mechanisms/second messenger systems through more general neurophysiological and neurochemical sequelae, the ultimate level of function for the central nervous system is in behaviour. However, the extent of its neuronal separation from initial ligand-receptor protein binding, through multiple efferent links, can create some difficulty in relating specific receptor subtype activation to any individual behavioural event(s); yet considerable progress has been made in this regard [ 13-151.
'D,-like'-'D2-like' interactions
One of the major factors influencing the functional parcellation of DA receptor subtype activation is the now substantial body of evidence that IDI-like' and IDz-like' receptors usually do not operate in isolation of their counterparts but participate in often complex ID1-like'-'Dz-like' interactions. These concepts had their origin in i 78 behavioural studies in rodents [ 16,171, with initial evidence for a 'permissive' or 'enabling' role of tonic or phasic D1 activation in the expression of typical Dz-mediated behaviours through co-operative/synergistic DI-D2 interactions; however, the symmetry of these interactions, in terms of a co-operative/synergistic role for D2 activation in typical D1-mediated behaviour, has remained less clear. As an additional complexity, other atypical DAergic behaviours appear to be regulated through oppositional D1-D2 interactions, by way of an inhibitory role of tonic or phasic D1/2 stimulation in the expression of such Dul-mediated responses. Although they evolved from studies of unconditioned motor behaviour, these concepts have been shown to apply to conditioned and consummatory behaviour, states of arousal and sleep, and to the regulation of seizure threshold. However, some forms of D1-and D2-determined behaviour, such as drug discrimination responding, appear, exceptionally, to be mediated in a generally independent, non-interactive manner [ 181.
The mechanism(s) by which ID1-like' and 'Dz-like' receptors interact has been the topic of intensive investigation [ 191. Co-operative/synergistic interactions congruent to those evident in behaviour have been identified electrophysiologically in each of the striatum, accumbens and globus pallidus ( [20, 21] ; but see [22] ); subsequently, these have been complemented also by similar neurochemical findings in the regulation of striatal Na', K+-ATPase activity [23] , the arachidonic acid cascade [24] and, most recently, the intermediate-early proto-oncogene c-fos [25] . Such interactions have also been reported to be mediated by guanine nucleotide-binding protein components, using both direct binding assays [26] and ligand competition techniques [27] ; however, both in our hands [28] and in those of colleagues [29] at least the former finding has not proved replicable. There endures evidence that both D1 and Dz receptors can each be activated independently in a manner sensitive to homologous but not to heterologous antagonism [30] ; additionally, the extent to which D1 and D2 receptors might be co-localized in the same neuronal membrane has been the topic of considerable debate [31-331. Furthermore, those D1 and D2 receptors that participate in co-operative/ synergistic interactions in the intact rodent appear to be rendered at least in part functionally uncoupled by the enduring removal of presynaptic DAergic function and associated induction of post-synaptic DA receptor up-regulation [ 19, 34, 35] . Until these issues are resolved, the extent to which co-operativelsynergistic IDllike'-'Dz-like' receptor interactions might be mediated directly via local neuronal processes or indirectly via more neurointegrative mechanisms remains to be clarified.
Regarding mechanisms of less well described and poorly understood oppositional 'D1-like'-'Dz-like' interactions, these appear not to be uncoupled by enduring removal of presynaptic DAergic function [36] . Opposite electrophysiological effects of D1 and D2 receptor stimulation continue to be described, most recently in the ventral pallidum, but these appear not to be subject to direct DI-Dz interaction on co-iontophoresis of selective agonists and antagonists [30] . Contrary to an earlier report [24] , a more recent study has described DI and D2 receptors to exert opposing effects on arachidonic acid release [37] . Similarly, in some contrast to a further previous report [25] , another recent study has found D1 and Dz receptors to subserve both co-operative/synergistic and oppositional interactions in the regulation of c-fos expression within distinct regions of the striatum [ 381. There persists the classical oppositional DI-Dz interaction in regulating the activity of striatal adenylate cyclase [2-61.
While the macroscopic anatomical localization of classical DAergic behaviours has been studied extensively for more than two decades and has led to similar studies concerning D2-mediated responses, such regional localization of D1-mediated behaviours and of DI-D2 interactions remains poorly understood; do they involve D1 and D2 receptors located in the same macroscopic (although not necessarily microscopic) region or in distinct but ultimately interconnected regions [ 191 ? Current interest centres on the caudal-central accumbens in the genesis of typical locomotor stimulation through D1-D2 synergism [39] . In recent studies [40] , the lateral striatum has emerged as a focus for the origin of typical D1 agonist-induced grooming, the most widely accepted behavioural model of D I receptor stimulation [ 15,161, and of atypical vacuous chewing, a somewhat more controversial model thereof [ 16,411; however, putative co-operative/ synergistic and oppositional DI-DZ interactions remain to be explored in this region.
'D,-like' receptors not linked to adenylate cyclase
Linkage to the stimulation of adenylate cyclase constitutes the defining characteristic of the classical D I receptor [2] , and this property extends to each of the 'DI-like' receptors identified to date by gene cloning (DIA-D and the primordial 'DI-like' entity [3-101); yet there has existed neuroanatomical and neurochemical evidence suggesting the existence of paradoxical IDI-like' receptors linked not to adenylate cyclase but to some alternative transduction system [42, 43] . In behavioural studies examining in rodents a series of benzazepine analogues of the prototypical D I partial agonist SK&F 38393, having from low (SK&F 75670) to high (but not full: SK&F 81297) efficacies, we found that these compounds each induced grooming behaviour to a common extent entirely unrelated to their varying efficacies to stimulate adenylate cyclase [44] . This would indicate either a receptor reserve large enough to confer maximal responsitivity on even a low efficacy partial D1 agonist or else mediation via a IDI-like' receptor that is not linked to adenylate cyclase.
T h e latter notion was strengthened by our finding that the new full-efficacy benzazepine D1 agonist SK&F 83189 was at best a modest inducer of grooming [45] while the novel full-efficacy isochroman D, agonist A 68930 was a powerful inducer of grooming [46] . Subsequently, both the discriminative stimulus [47] and seizure-promoting [48] properties of the benzazepine partial D1 agonists were shown to be unrelated to their varying efficacies to stimulate adenylate cyclase; in an entirely complementary manner, their electrophysiological actions on accumbens neurons after iontophoretic application [49] and on ventral pallidal neurons after systemic administration [50] appeared to be similarly unrelated to efficacy of adenylate cyclase stimulation. These findings are consonant with recent neurochemical studies that continue to suggest the existence of IDI-like' receptor(s) that are linked not to adenylate cyclase but rather to phosphoinositol metabolism [5 13 ; in particular, studies using this series of benzazepine derivatives [52] have indicated a ID1-like' receptor mediating phosphoinositide hydrolysis that is pharmacologically distinct from the classical D, receptor and indeed the DIA-D cyclase-coupled receptor family.
Functionally, interpretation of the apparent lack of relationship between behavioural activity and efficacy to stimulate adenylate cyclase is not straightforward; while it is consistent with mediation via a 'DI-like' receptor not linked to adenylate cyclase, other explanations cannot be excluded in the absence of more direct evidence. Recently, another benzazepine analogue, SK&F 83959, has been reported to be unable to stimulate adenylate cyclase and, indeed, it inhibits the stimulation of adenylate cyclase induced by DA, i.e. it shows all the defining characteristics of a D I antagonist, yet this compound appears to exert some paradoxical D, receptor agonist-like effects on behaviour [53, 54] . Subsequently, we described preliminary studies [55] that indicated SK&F 83959 to induce grooming, together with vacuous chewing behaviour; this would appear to be inconsistent with mediation of grooming via the classical D1 or any 'DI-like' receptor linked to the stimulation of adenylate cyclase, but responses to SK&F 83959 were not characterized in detail. More recently, we have reported SK&F 83959-induced grooming to be readily blocked both by the prototypical benzazepine selective D1 antagonist SCH 23390 and by the novel isoquinoline D1 antagonist BW 737C, each of which is a potent inhibitor of the stimulation of adenylate cyclase by DA [56] .
T h e profile of responsivity to SK&F 83959 is not compatible with in vivo generation of an active D, agonist metabolite [56] and, importantly, its failure to exert any significant stimulation of adenylate cyclase has been replicated ( [57] , J. C. Stoof, personal communication).
Thus, it would seem likely that SK&F 83959 exerts its paradoxical induction of grooming behaviour directly through stimulation of a IDIlike' receptor that is (i) not linked to adenylate cyclase and (ii) thus able to respond similarly to drugs having a common affinity for this 'DI-like' site independent of whether they exert 'agonist' or 'antagonist' actions at the classical adenylate cyclase-coupled DI receptor. In relation to SK&F 83959-induced vacuous chewing, this response is also phenomenologically identical to that produced by the isochroman selective D1 agonist A 68930, which shows full efficacy to stimulate adenylate cyclase; additionally, the vacuous chewing responses to SK&F 83959 and to A 68930 were not blocked by SCH 23390, which induced vacuous chewing when given alone [46, 56] . Although the involvement of non-DAergic mechanisms cannot be excluded, vacuous chewing might be mediated via some other, novel DA receptor subtype at which the Overall, a convergence of behavioural, electrophysiological and neurochemical findings strengthens the concept of functionally distinct, cyclase-independent IDl-like' receptors. Furthermore, such data indicate that the terms 'agonist' and 'antagonist', as defined in terms of classical D1-mediated effects on adenylate cyclase, may be inappropriate for such IDI-like' receptors pending their indentification and characterization in terms of an alternative second messenger/transduction system.
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Species differences and clinical implications
It must be re-emphasized that, as with the bulk of general biomedical research, the substantive majority of the functional studies outlined above have been conducted using rodents, usually laboratory rats; thus, the schemas deriving therefrom must be evaluated in that context. From early in the exploration of these issues, contrary findings in non-human primate species have been a cause of concern: for example, while the partial D, agonist SK&F 38393 acted synergistically with D2 agonists in rodents, indicative of cooperativelsynergistic DI-D2 interactions, it appeared to antagonize the effects of D2 agonism in non-human primates; furthermore, the antiparkinsonian activity predicted for SK&F 38393 in rodent models was not sustained by its lack of therapeutic efficacy, and indeed it exacerbated parkinsonian features both in the non-human primate 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model and in preliminary studies in patients [ 19,591. Subsequently, these contradictions have become yet more complex: 'lower efficacy' partial D1 agonists appear particularly to exert effects in non-human primates that are opposite to those they exert in rodents; 'higher efficacy' partial D1 agonists appear somewhat less paradoxical in this regard; 'full efficacy' D I agonists demonstrate properties in nonhuman primates that are generally more in keeping with their effects in rodents [60-671.
Attempted resolution of the above profiles has been obfuscated by seeking to interpret behavioural studies undertaken in non-human primates v i s -h i s D I agonist efficacies determined usually in rodent tissue. On systematic examination, SK&F 38393 was reputed to show considerably less D1 'agonist' efficacy and considerably greater D1 'antagonist' activity in nonhuman primate than in rodent tissue in terms of adenylate cyclase parameters, in a manner consistent with its more D1 'antagonist'-like profile in the former species; it was suggested that a lower D1 receptor reserve in primates than in rodents might underlie these differences [68] . 
demonstrates full efficacy in all species
In the face of such contradictions concerning 'partial' D l agonists, attention must focus on possible methodological differences between studies, particularly as they relate to determination of adenylate cyclase activity through cyclic-AMP production. It has been suggested that 'high' or 'full'-efficacy D1 agonists, either alone or in combination with D2 agonism, are of clinical potential in Parkinson's disease in terms of therapeutic activity and reduced dyskinetogenic 
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Recent Advances in Brain Dopaminergic Systems studies using transgenic mice with selective deletion of the DIA receptor through homologous recombination [76, 77] should constitute a n important new route to addressing these issues.
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